IL-18 Binding Protein-Producing Cells Attenuate Anemia in Murine Macrophage Activation Syndrome.
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
24
01
2023
accepted:
23
03
2023
medline:
17
5
2023
pubmed:
19
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
IL-18 is a pleiotropic immunoregulatory cytokine of the IL-1 family. IL-18 has been identified as a potent IFN-γ inducer in synergy with IL-12 and IL-15 and thus as a powerful Th1 cell-polarizing cytokine. IL-18 activity is regulated by its naturally occurring soluble inhibitor IL-18 binding protein (IL-18BP), the production of which is stimulated by IFN-γ in a negative feedback loop. Circulating levels of IL-18BP are elevated, and unbound bioactive free IL-18 is thus not detectable in the circulation in physiologic conditions. However, emerging evidence indicates that the IL-18/IL-18BP balance could be dysregulated in macrophage activation syndrome (MAS), as mirrored by the presence of free IL-18 in the circulation of patients with MAS. Herein, we sought to identify IL-18BP-producing cells in a murine CpG-induced MAS model using IL-18BP knock-in tdTomato reporter mice. Endothelial cells, tissue-resident macrophages, and neutrophils appeared as major cellular sources of IL-18BP. We also identified extramedullary and medullary early erythroid progenitors as IL-18BP-producing cells in an IFN-γ-dependent manner. This finding suggests a novel regulation of IL-18 activity by erythroid precursors, which are likely involved in the prevention of the negative effects of IL-18 on erythropoiesis. Indeed, coherent in vivo and in vitro results indicate that IL-18 indirectly impairs erythropoiesis while favoring myelopoiesis and thus contributes to anemia associated with MAS and potentially with other IL-18-driven inflammatory diseases. In conclusion, IL-18BP production by endothelial cells, neutrophils, macrophages, and erythroid precursors attenuates the anemia associated with murine CpG-induced MAS.
Identifiants
pubmed: 37074208
pii: 263625
doi: 10.4049/jimmunol.2300065
pmc: PMC7614543
mid: EMS173287
doi:
Substances chimiques
Carrier Proteins
0
Cytokines
0
Interleukin-18
0
interleukin-18 binding protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1790-1803Subventions
Organisme : Swiss National Science Foundation
ID : 201269
Pays : Switzerland
Informations de copyright
Copyright © 2023 The Authors.
Références
Haematologica. 2013 Oct;98(10):1633-40
pubmed: 23996485
Blood. 2014 Feb 20;123(8):1137-45
pubmed: 24357729
Cells. 2020 May 18;9(5):
pubmed: 32443494
Lancet. 2014 Apr 26;383(9927):1503-1516
pubmed: 24290661
J Clin Invest. 2011 Jun;121(6):2264-77
pubmed: 21576823
Intern Med. 2009;48(6):421-6
pubmed: 19293540
Cytokine. 2001 Jun 21;14(6):334-42
pubmed: 11497494
Blood. 2004 Apr 1;103(7):2816-21
pubmed: 14604961
J Immunol. 2020 Aug 15;205(4):1167-1175
pubmed: 32651219
Blood. 2019 Jul 11;134(2):147-159
pubmed: 31015190
Front Immunol. 2013 Oct 08;4:289
pubmed: 24115947
Blood. 2011 Sep 1;118(9):2578-88
pubmed: 21725055
Arthritis Rheum. 2008 Sep;58(9):2892-6
pubmed: 18759271
Anemia. 2020 Feb 07;2020:3041738
pubmed: 32095285
Blood. 2018 Mar 29;131(13):1430-1441
pubmed: 29295842
Blood. 2018 Jun 7;131(23):2581-2593
pubmed: 29666112
Arthritis Rheumatol. 2018 Jun;70(6):963-970
pubmed: 29409136
Immunol Rev. 2018 Jan;281(1):138-153
pubmed: 29247988
J Cell Mol Med. 2009 Aug;13(8B):1987-1994
pubmed: 19046253
PLoS One. 2012;7(6):e38751
pubmed: 22761702
Blood. 2006 Aug 15;108(4):1402-5
pubmed: 16574947
Rheumatology (Oxford). 2010 Mar;49(3):441-9
pubmed: 20019066
Immunity. 1999 Jan;10(1):127-36
pubmed: 10023777
Semin Immunol. 2013 Dec 15;25(6):439-48
pubmed: 24275602
Rheumatology (Oxford). 2003 Mar;42(3):442-5
pubmed: 12626794
Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1190-5
pubmed: 10655506
PLoS One. 2010 Jan 13;5(1):e8663
pubmed: 20072626
Nature. 1996 Feb 15;379(6566):591
pubmed: 8628393
Front Immunol. 2019 Aug 27;10:2014
pubmed: 31507607
Leuk Lymphoma. 2014 Feb;55(2):231-2
pubmed: 23713457
J Exp Med. 2011 Jun 6;208(6):1203-14
pubmed: 21624938
FASEB J. 2009 Jan;23(1):194-203
pubmed: 18780764
Infect Immun. 1989 Feb;57(2):590-5
pubmed: 2492265
J Immunol. 2002 Apr 1;168(7):3608-16
pubmed: 11907126
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8737-42
pubmed: 17502613
J Cell Physiol. 1995 Jan;162(1):134-8
pubmed: 7814445
Front Immunol. 2017 Aug 28;8:1020
pubmed: 28900426
Rheumatology (Oxford). 2016 Dec;55(12):2237-2247
pubmed: 27616144
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1906-10
pubmed: 15684062
J Allergy Clin Immunol. 2017 May;139(5):1698-1701
pubmed: 27876626
J Immunol. 1985 Oct;135(4):2507-12
pubmed: 2411798
Biochim Biophys Acta Gene Regul Mech. 2018 Mar;1861(3):191-199
pubmed: 29409936
Gut. 2004 Mar;53(3):392-400
pubmed: 14960523
BMC Cancer. 2016 Apr 11;16:270
pubmed: 27068103
J Immunol. 2016 Mar 15;196(6):2492-503
pubmed: 26880764
J Immunol. 2002 Mar 1;168(5):2282-7
pubmed: 11859116
Blood. 2005 Nov 15;106(10):3483-9
pubmed: 16020503
Biochem Biophys Res Commun. 2000 Jan 27;267(3):960-3
pubmed: 10673399
J Immunol. 2001 Dec 15;167(12):7038-43
pubmed: 11739524
Arthritis Rheum. 2011 Dec;63(12):3672-80
pubmed: 22127690
Blood. 2018 Mar 29;131(13):1442-1455
pubmed: 29326099
J Exp Med. 2019 Aug 5;216(8):1777-1790
pubmed: 31213488
Nat Med. 2004 Feb;10(2):187-92
pubmed: 14745443
Cytokine. 2015 Nov;76(1):25-37
pubmed: 26185894
J Clin Invest. 2004 May;113(9):1271-6
pubmed: 15124018
Blood. 1996 May 15;87(10):4149-57
pubmed: 8639773